Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

[1]  J. Shim,et al.  Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemotherapy , 2019, International journal of cancer.

[2]  Young Tae Kim,et al.  Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study , 2018, Journal of gynecologic oncology.

[3]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[4]  Tanja Fehm,et al.  BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Avan,et al.  Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer , 2018, Journal of cellular physiology.

[6]  Yong-wen Huang.  Association of BRCA1/2 mutations with ovarian cancer prognosis , 2018, Medicine.

[7]  Young Tae Kim,et al.  Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. , 2018, Gynecologic oncology.

[8]  Richard A. Moore,et al.  Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer , 2017, Clinical Cancer Research.

[9]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[10]  P. Fasching,et al.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.

[11]  G. Scambia,et al.  BRCA mutational status, initial disease presentation, and clinical outcome in high‐grade serous advanced ovarian cancer: a multicenter study , 2017, American journal of obstetrics and gynecology.

[12]  Young Tae Kim,et al.  External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma , 2017, Journal of gynecologic oncology.

[13]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[14]  G. Scambia,et al.  Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. , 2016, European journal of cancer.

[15]  A. Sokolenko,et al.  High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. , 2015, Cancer letters.

[16]  Bin Yang,et al.  Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. , 2015, Gynecologic oncology.

[17]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[18]  A. Tinker,et al.  Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[21]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Narciso Olvera,et al.  Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma , 2012, Modern Pathology.

[23]  Funda Meric-Bernstam,et al.  Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Chi,et al.  Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. , 2011, Gynecologic oncology.

[25]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[26]  J. Lubiński,et al.  Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Nafisi,et al.  A comparative study on the interaction of cis- and trans-platin with DNA and RNA. , 2009, DNA and cell biology.

[28]  G. Scambia,et al.  Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. , 2008, American journal of obstetrics and gynecology.

[29]  S. Johnston,et al.  Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  A. Sato,et al.  Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. , 2008, Japanese journal of clinical oncology.

[31]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Ashworth,et al.  Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy , 2006, Clinical Cancer Research.

[33]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  J. Farmer,et al.  Incorporation of As , 2002 .

[36]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[37]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.